Presentations

Opthea To Present at H.C. Wainwright Annual Global Life Sciences Conference

Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at H.C. Wainwright Annual Global Life Sciences Conference May 23-25.

Webcast

Opthea To Present at Citi Biopharma Virtual Co-Panel day

Dr Megan Baldwin, the Company’s Chief Executive Officer, will present on the Citi Biopharma virtual Co-Panel day Ophthalmology Panel on May 18, 2022

Webcast

ARVO 2022 Annual Meeting

Opthea Presented Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy at ARVO 2022

Poster Presentation

ASX Small – Mid Cap Conference 2022

Opthea Presented at the ASX Small – Mid Cap Conference 2022

Presentation RecordingProactive Investor

Oppenheimer’s 32nd Annual Healthcare Conference

Opthea to Present at the Oppenheimer Annual Healthcare Conference – webcast on Tuesday, March 15 at 8:40 am ET

Webcast

Angiogenesis 2022 – Prof Cheung presentation of PCV data

OPT-302 Combination Therapy in Polypoidal Choroidal Vasculopathy.

 

Download PDF

SVB Leerink 11th Annual Healthcare Conference

Opthea to present at the SVB Leerink 11th Annual Healthcare Conference — webcast on Thursday, February 17 at 2:20 pm ET (Friday, February 18, 6:20 am AEDT)

 

Webcast

H.C. Wainwright BIOCONNECT Conference

Opthea to present at the H.C. Wainwright BIOCONNECT Conference — webcast on Monday, January 10 at 7:00 am ET (Monday, January 10, 11:00 pm AEDT)

 

Webcast
Opthea Corporate Presentation May 2022

Download the Presentation Slides

MST Access Initiation of Coverage report: In its ‘Lines’ of Sight

Download the report

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call

Download the transcript

Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York
Opthea Corporate Presentation October 2021

Download the presentation slides

MST Access Initiation of Coverage report: In its ‘Lines’ of Sight

Download the report

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call

Download the transcript

Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York

Presentation